Preliminary results of the Phase III trial of China's Coxing new crown vaccine in Chile show good safety and immunogenicity

Chile about the team of experts was held on the 17th at the San Diego conference to introduce the initial situation Chinese company Sinovac new crown vaccine Ⅲ clinical trials in Chile since November last year, confirmed that Sinovac vaccine has a good safety and immune immunogenicity.

On the same day, the Coxing Vaccine Phase III clinical trial team led by the Catholic University of Chile submitted reports on vaccine quality, safety and immunogenicity to the Chilean Ministry of Health, the Ministry of Science and Technology and the Institute of Public Health.

In terms of vaccine safety, experts said that preliminary research results based on the participation of about 500 volunteers showed that there was no serious adverse reaction.

Experts said that studies on the immunogenicity of the vaccine showed that the increase in antibodies to the new coronavirus could be detected in some vaccinated patients 14 days after the first dose of vaccination.

Experts also pointed out that there is no difference between the immune response of Kexing vaccine in people over 60 years old and people under 60 years old.

It is reported that the Phase III clinical trial of Coxing Vaccine in Chile has recruited more than 2,000 volunteers and conducted it in 8 centers across Chile.

Chile launched a nationwide large-scale vaccination of the new crown vaccine on February 3 this year.